



Onorati et al Acquired Cardiovascular DiseaseSuccessful surgical treatment of chronic ischemic mitral
regurgitation achieves left ventricular reverse remodeling but does
not affect right ventricular function
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Objective: To evaluate left-sided and right-sided heart echocardiographic results after restrictive mitral annulo-
plasty in chronic ischemic mitral regurgitation.
Methods: Left atrial diameter, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left
ventricular ejection fraction, left ventricular indexed mass, coaptation depth, transmitral mean gradient, systolic
pulmonary arterial pressure, tricuspid annular plane systolic excursion, right ventricular ejection fraction, and tri-
cuspid insufficiency grading were evaluated preoperatively, postoperatively, at 6 months, and at the end of the
follow-up period in 64 patients undergoing restrictive mitral annuloplasty and coronary artery bypass grafting.
Recurrence of chronic ischemic mitral regurgitation was defined as 2þ/4þ grade or greater mitral regurgitation
at any time postoperatively.
Results: Twenty-two months of freedom from recurrent chronic ischemic mitral regurgitation was 58.2% 
9.8%. Recurrent chronic ischemic mitral regurgitation did not lead to reverse remodeling of left atrial diameter,
left ventricular end-diastolic diameter, left ventricular end-systolic diameter, and ventricular indexed mass
(P¼ not significant), with increased coaptation depth, parallel to follow-up chronic ischemic mitral regurgitation
worsening. Effective restrictive mitral annuloplasty induced reverse remodeling of left ventricular end-diastolic
diameter, left ventricular end-systolic diameter, and ventricular indexed mass, improved left ventricular ejection
fraction, shortened coaptation depth, and improved mean gradient (P .014). Recurrent chronic ischemic mitral
regurgitation in patients without tricuspid surgery prevented improvements of systolic pulmonary arterial pres-
sure, tricuspid annular plane systolic excursion, right ventricular ejection fraction, worsening New York Heart
Association (P ¼ .003), and daily diuretic need (P ¼ .008), whereas effective restrictive mitral annuloplasty pro-
gressively improved tricuspid insufficiency grading, systolic pulmonary arterial pressure, right ventricular ejection
fraction, tricuspid annular plane systolic excursion, New York Heart Association, and diuretic need (P  .013).
Patients undergoing tricuspid annuloplasty did not show any improvement of systolic pulmonary arterial pressure,
right ventricular ejection fraction, and tricuspid annular plane systolic excursion regardless of the recurrence
of chronic ischemic mitral regurgitation (P ¼ not significant), although effective restrictive mitral annuloplasty
improved tricuspid insufficiency grading, New York Heart Association, and daily diuretic need (P  .010).
Conclusion: Effective restrictive mitral annuloplasty induces reverse left ventricular remodeling. Absence of
recurrent chronic ischemic mitral regurgitation improves tricuspid insufficiency grading, systolic pulmonary
arterial pressure, right ventricular ejection fraction, tricuspid annular plane systolic excursion, New York Heart
Association, and diuretic need in patients who do not undergo tricuspid surgery, but only tricuspid insufficiency
grading, New York Heart Association, and daily diuretic need in patients who undergo tricuspid surgery.Although there is no evidence from randomized trials, obser-
vational studies have shown that treatment of chronic ische-
mic mitral regurgitation (CIMR) by mitral valve repair and
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outcome than CABG alone.1 It has been demonstrated that
restrictivemitral annuloplasty (RMA)þCABGhas a positive
effect on short-term follow-up reverse remodeling.2 Debate
continues, however, with regard to survival benefits,3 which
is also reflected in the latest American College of Cardiol-
ogy/American Heart Association Guidelines.4 Nevertheless,
despite that the results of mitral repair for CIMR have im-
proved over the last 20 years, ongoing dissatisfaction with
outcomes and recurrences have yielded many different ap-
proaches to CIMR.5 Accordingly, the long-term efficacy
of RMA is still unclear, and recurrence of CIMR has beenardiovascular Surgery c Volume 138, Number 2 341




CABG ¼ coronary artery bypass grafting
CD ¼ coaptation depth
CIMR ¼ chronic ischemic mitral regurgitation
LAD ¼ left atrial diameter
LVEDD ¼ left ventricular end-diastolic diameter
LVEF ¼ left ventricular ejection fraction
LVESD ¼ left ventricular end-systolic diameter
LVMi ¼ left ventricular mass index
mean Dp ¼ transmitral mean gradient
NYHA ¼ New York Heart Association
PAPs ¼ systolic pulmonary arterial pressure
RMA ¼ restrictive mitral annuloplasty
RVEF ¼ right ventricular ejection fraction
TAPSE ¼ tricuspid annular plane systolic
excursion
TI ¼ tricuspid insufficiency
predominantly related to progressive left ventricular dilation
and responsible for recurrent congestive heart failure and
follow-up morbidity and mortality.6 Few literature data exist
regarding mid- to long-term echocardiographic results after
RMA.7 Finally, despite the supposed beneficial effects of
RMA in terms of congestive heart failure and left ventricular
reverse remodeling, little is known about the fate of the right
ventricle after RMA, although a recent study has proven
RMA to act as a native mitral stenosis.8
This study evaluates the midterm clinical and echocardio-
graphic results of a consecutive series of patients undergoing
RMAþCABG for CIMR, focusing on left and right ventric-
ular function and remodeling, with subgroup analysis in
patients with tricuspid surgery.
MATERIALS AND METHODS
Patients and Surgery
Between August 2004 and September 2007, 66 consecutive patients who
were admitted with CIMR and underwent RMA þ CABG with at least
6 months of postoperative follow-up were enrolled. Institutional review
board approved conducting this study and waived the need for individual
consent. CIMR was defined as mitral regurgitation occurring more than 1
week after myocardial infarction with 1 or more left ventricular segmental
wall motion abnormalities, significant coronary disease in the territory
supplying the wall motion abnormality, and structurally normal mitral valve
leaflets and chordae tendinae.5 Therefore, patients with organic mitral
disease (eg, myxomatous, rheumatic) were excluded from the study. All pa-
tients had coronary artery disease and CIMR grade 3þor 4þat preoperative
echocardiography (semiquantitatively from color-flow Doppler). Patients
demonstrating 2þ CIMR underwent further provocative intraoperative
testing (rapid infusion of volume until the wedge pressure reached 16 to
18 mm/Hg or phenylenephrine administration until mean arterial pressure
reached 100 mm/Hg)9 and were enrolled whenever 3þ to 4þmitral regurgi-
tation was shown.
CIMR was always caused by post-infarction restrictive systolic leaflet
motion (Carpentier type IIIb) (Table 1), severe annular dilation resulting
from ischemic dilated cardiomyopathy (Carpentier type I), or a combination342 The Journal of Thoracic and Cardiovascular Suof both (Carpentier type I þ IIIb) (Table 1). Patients with concomitant
surgery (eg, surgical ventricular restoration, papillary sling, aortic valve
surgery), apart from tricuspid annuloplasty, were excluded from the study.
Accordingly, tricuspid regurgitation 2þor greater or tricuspid regurgitation
less than 2þin the presence of dilated tricuspid annulus exceeding 21mm/m2
indexed to body surface area at transthoracic echocardiography indicated
concomitant tricuspid annuloplasty.10
All patients had symptoms of heart failure, and the majority presented
New York Heart Association (NYHA) class III or IV (Table 1). Mean logis-
tic European System for Cardiac Operative Risk Evaluation was 10.8 3.1.
The diagnosis of chronic obstructive pulmonary disease was based on the
Summit database definition: Each patient required treatment for chronic pul-
monary compromise or had a forced expiratory volume in 1 second less than
75% of predicted value or a forced expiratory volume in 1 second to forced
expiratory vital capacity less than 0.7 at preoperative spirometry. Baseline
characteristics are presented in Table 1.
Surgery was performed by the same surgeon (A.R.) in all cases through
a median sternotomy. The ascending aorta was always cannulated, and ve-
nous return was always accomplished through a double caval cannulation.
All patients underwent left internal thoracic artery to the left anterior
descending grafting. The radial artery was used in 18 patients and always
harvested as a pedicle with an ultrasonic scalpel (Ethicon Endo-Surgery,
Cincinnati, Ohio). Saphenous veins were always harvested from the best
side, as detected by preoperative echo-Doppler scanning. All grafts under-
went intraoperative transit-time analysis, and unsatisfactory results always
led to redo CABG.11 The mitral valve was exposed through a longitudinal
atriotomy along the Waterston’s groove in all patients. Ring size (Carpent-
ier-Edwards Physio ring; Edwards Lifesciences, Irvine, Calif or Carpentier-
McCarthy-Adams ring, Edwards Lifesciences) was determined after careful
measurement of the height of the anterior leaflet and intertrigonal distance,
and then downsizing by 2 sizes (ie, size 26 when measuring 30). Complete
symmetric rings (Carpentier-Edwards Physio ring) were preferred when
TABLE 1. Preoperative and intraoperative data
Variables No. of patients % (global population)
Age (y) 69.9  2.3 —
Sex (male) 41 64.1%
NYHA 3.4  0.6 —




Left main stem disease 46 71.9%
Previous AMI 28 43.8%
Recent (<4 wk) AMI 36 56.3%
Anterior AMI 16 25.0%
Posterior AMI 38 59.4%




No. of CABG surgeries 2.3  1.1 —
LITA CABG 64 100%
RA CABG 12 18.8%
ACC time 73.3  4.1 —
CPB time 135.5  12.2 —
Tricuspid annuloplasty 16 25%
NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease;
AMI, acute myocardial infarction; STEMI, ST elevation myocardial infarction; CABG,
coronary artery bypass graft; LITA, left internal thoracic artery; RA, radial artery; ACC,
aortic crossclamp; CPB, cardiopulmonary bypass.rgery c August 2009
Onorati et al Acquired Cardiovascular Disease
A
C
DCIMR was predominantly caused by annular dilation (Carpentier type I),
and complete asymmetric rings (Carpentier-McCarthy-Adams ring) were
preferred when inferior or posterolateral infarction caused restrictive sys-
tolic leaflet motion (Carpentier type IIIb). Tricuspid annuloplasty was al-
ways accomplished with a Carpentier Edwards MC3 ring (Edwards
Lifesciences). By using the Carpentier’s measurement technique, the appro-
priate ring size was selected on the basis of the length of the attachments of
the tricuspid septal leaflet and the surface area of the anterior leaflet, and
then downsized by at least 1 measure. Ring implantation was performed
by placing 8 to 10 mattress sutures through the tricuspid annulus around
the orifice, avoiding the area of atrioventricular conduction tissue.
Cardiopulmonary bypass was standardized: a Dideco (Mirandola, Mod-
ena, Italy) tubing set, which included a 40-mm filter, Stockert roller pump
(Stockert Instrumente, Munich, Germany), and hollow fiber membrane
oxygenator (Dideco D903 Avant, Mirandola). Myocardial protection was
always achieved with intermittent antegrade and retrograde hyperkalemic
blood cardioplegia.
Anticoagulation Protocol
It was institutional policy to start 4000 IU low molecular weight heparin
(nadroparin) 2 times per day 8 hours after surgery. Warfarin therapy was
started on the second postoperative day, targeted to an international normal-
ized ratio between 2.0 and 3.0 in patients with sinus rhythm and between 2.5
and 3.5 in patients with atrial fibrillation, until the third postoperative
month. Oral antiplatelet therapy (acetylsalicylic acid 150 mg/d) was started
thereafter.
Echocardiography
Echocardiography was always accomplished by the same 3 cardiolo-
gists, using a VIVID 7 Pro ultrasound machine (GE Technologies,
Milwaukee, Wis). All patients underwent preoperative transthoracic and
transesophageal echocardiography. Transthoracic echocardiographic evalu-
ation consisted of standard echocardiography examination, including grad-
ing of severity of CIMR (semiquantitatively from color-flow Doppler), left
atrial diameter (LAD), left ventricular end-diastolic diameter (LVEDD), left
ventricular end-systolic diameter (LVESD), left ventricular ejection fraction
(LVEF), left ventricular mass index (LVMi), coaptation depth (CD), trans-
mitral mean gradient (mean Dp), systolic pulmonary arterial pressure
(PAPs), tricuspid annular plane systolic excursion (TAPSE), and tricuspid
insufficiency (TI) grading. Apical 4-chamber view was accomplished to
measure severity of CIMR, LAD, LVEF (Simpson’s method), CD, and
transmitral mean Dp. Parasternal long-axis view was used to measure
LVEDD and LVESD by M-mode.
The severity of CIMR was determined by the ratio of maximum color
Doppler regurgitant jet area to left atrial area. CIMR grade was estimated
as trivial, mild, moderate, or severe on the basis of ratios of 0% to 10%,
10% to 20%, 20% to 40%, and greater than 40%, respectively.10 Mean
preoperative CIMR was 3.4  0.6 (range 2þto 4þ). Indexed left ventricular
mass was calculated according to Devereux’s formula.12 TI was evaluated
using the apical 4-chamber view. TI was graded as trace (1þ), mild (2þ),
moderate (3þ), or severe (4þ) when the jet area occupied less than 10%,
10% to 20%, 20% to 33%, or more than 33% of the right atrial area, re-
spectively.10 Mean preoperative TI was 2.0  0.6 (range 2þ to 4þ). TAPSE
was measured by 2-dimensional echocardiography from the apical 4-cham-
ber view at the right ventricular free wall level, as described by Kaul and
colleagues.13 Finally, right ventricular ejection fraction (RVEF) was calcu-
lated after TAPSE analysis from an apical 4-chamber view, according to
Kaul and colleagues13 and Ueti and colleagues.14 Mitral valve repair was
considered successful at intraoperative transesophageal echocardiography
if there was no residual mitral regurgitation after cardiopulmonary bypass
discontinuation with an achieved adequate preload (central venous pressure
10–15 mm Hg). All patients also had intraoperative assessment of left ven-
tricular function. Postoperatively, transthoracic echocardiography was re-The Journal of Thoracic and Cpeated before discharge, at early follow-up (6 months), and at the end of
follow-up. Mean follow-up was 22.3  14.8 months (range 6–55 months).
Recurrence of CIMR was defined as 2þ/4þgrade or greater mitral regurgi-
tation at any time postoperatively at semiquantitative color-flow Doppler
analysis and recorded in the institutional database. Follow-up was closed
on April 1, 2008, and was 100% completed.
Clinical Assessment
NYHA was determined preoperatively, up to 5 days before surgery, at
discharge, at 6 months, and at the end of follow-up in the outpatient clinic.
As a surrogate outcome of heart failure, need and dose of furosemide were
assessed at the same time points. Deaths and episodes of acute congestive
heart failure, hospital readmission, and redo mitral/coronary surgery during
the follow-up were recorded.
Statistical Analysis
Statistical analysis was performed by the Statistical Program for the So-
cial Sciences for Windows, version 13.0 (SPSS Inc, Chicago, Ill). Continu-
ous variables are presented as mean  standard deviation, and categoric
variables are presented as absolute numbers or percentages. Normally distrib-
uted continuous variables were compared using the unpaired t test, whereas
the Mann–Whitney U test was used for not normally distributed variables.
Categoric variables were analyzed using the chi-square or Fisher’s exact
test. Comparison between and within groups was made using 2-way analysis
of variance for repeated measures. Follow-up survival and freedom from
congestive heart failure, hospital readmission, and redo surgery were deter-
mined with Kaplan–Meier life table analysis. Log-rank test was performed
to ascertain differences between patients with and without CIMR recurrence.
RESULTS
Hospital Outcome
Preoperative and intraoperative data are reported in Table
1. Two patients demonstrated persistent intraoperative 1 to
2þCIMR despite 2-size undersizing and underwent mitral
valve replacement after reestablishment of cardiopulmonary
bypass. These 2 patients were excluded from the study be-
cause of the different surgical therapy. Successful mitral
valve repair was achieved in all the remaining 64 patients,
regardless of the degree of leaflet tethering. Therefore,
only 64 patients were enrolled and followed up. Mean mitral
ring size was 25.8 1.6 mm (median size 26 mm; range 24–
32 mm). There were no cases of systolic anterior motion or
significant mitral stenosis (mean transvalvular gradient, 4.6
 0.4 mm Hg; mean mitral valve area, 2.8  0.9 cm2). Six-
teen patients (25.0%) underwent tricuspid annuloplasty.
Mean tricuspid ring size was 27.5  1.2 mm (median size
28 mm; range 26–30 mm). Postoperative transit-time flow-
metry demonstrated good values in all CABG: Left internal
thoracic artery to left anterior descending mean flow was
32.2  15.8 mL/min (pulsatile index of 1.6  1.2); radial
artery mean flow was 48.6  24.3 mL/min (pulsatile
index of 1.2  0.8); and saphenous vein mean flow was
34.7 10.9 mL/min (pulsatile index of 1.9 0.8). Hospital
mortality was 6.2% (4 patients, all showing preoperative
4þCIMR). One patient had perioperative acute myocardial
infarction (1.5%), 3 patients had postoperative low output
syndromes (4.6%) requiring prolonged intraaortic balloonardiovascular Surgery c Volume 138, Number 2 343
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Dpump (>48 hours) and inotropic support with intravenous
dobutamineþ levosimendan; and 11 patients (17.2%) had
paroxysmal atrial fibrillation requiring intravenous amiodar-
one. Two patients (3.1%) had pneumonia, 1 patient (1.5%)
had acute renal failure, and 1 patient (1.5%) had cognitive
dysfunction. Overall hospital morbidity accounted for 19 pa-
tients (29.6%). Intensive care stay was 41.2  8.3 hours
(range 32–84 hours), and hospital stay was 6.8  2.2 days.
Follow-up Clinical Outcome
Mean follow-up was 22.3  14.8 months (range 6–55
months). Two patients died of acute congestive heart failure
during follow-up, both showing recurrence of CIMR at fol-
low-up, giving a 22.2  15.3 months actuarial survival of
96.5%  2.5% (Figure 1, A). Both patients died within
the 6-month follow-up period; therefore, 58 patients surviv-
ing beyond the sixth month were completely followed up
with echocardiography.
Eight patients had congestive heart failure during follow-
up, 10 patients required hospitalization because of cardiaccauses, and 2 patients underwent re-revascularization, giving
a 21.3 15.6months actuarial freedom from congestive heart
failure of 71.6% 10.5% (Figure 1, B), 21.3 15.7 months
freedom from hospitalization of 65.2%  10.7% (Figure 1,
C), and 22.1  15.3 months freedom from reintervention of
94.2  4.2 (Figure 1, D). Recurrence of CIMR 2þor greater
at echocardiographic follow-up developed in 16 of 60 pa-
tients who were discharged from the hospital (26.6%). Of
these patients, 2 died during early follow-up, as already re-
ported; therefore, 14 (24.1%) of 58 patients surviving more
than 6 months had CIMR 2þ or greater, resulting in 22.5 
15.8 months of actuarial freedom from CIMR (58.2% 
9.8%) (Figure 2, A). Patients with recurrence of CIMR did
not show differences in the type of implanted ring (8/22
[26.7%] Physio Ring vs 6/22 [21.4%] Carpentier-McCar-
thy-Adams, P ¼ .438) and the mean ring size (Physio 28.3
 1.7 mm vs Carpentier-McCarthy-Adams 29.0  1.1 mm;
P ¼ .360). Accordingly, residual CIMR did not differ be-
tween ring type at discharge (Physio 0.9  0.6 vs Carpent-
ier-McCarthy-Adams 0.9  0.6, P ¼ .965), 6 monthsFIGURE 1. Actuarial survival (A), and freedom from CHF (B), hospitalization (C), and reintervention (D).
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DFIGURE 2. Freedom from  2þCIMR recurrence (A) and freedom from CHF (B), hospitalization (C), and reintervention (D) between patients with and
without CIMR recurrence. CIMR, Chronic ischemic mitral regurgitation.(Physio 1.1 0.6 vs Carpentier-McCarthy-Adams 0.8 0.7,
P¼ .093), and the end of follow-up (Physio 1.2 1.0 vs Car-
pentier-McCarthy-Adams 0.9  0.9, P ¼ .182). However,
when patients with CIMR were compared with those without
CIMR, a significantly lower freedom from CHF (log-rank P
¼ .0001; Figure 2, B), hospitalization (P ¼ .0001; Figure 2,
C), and reintervention (P ¼ .034; Figure 2, D) was demon-
strated. When functional status was considered, despite the
fact that both groups of patients, with or without recurrentThe Journal of Thoracic and CCIMR, improved their NYHA, those without CIMR during
follow-up showed significantly better recovery of NYHA
and a significantly lower need for diuretics (Table 2). Accord-
ingly, recurrent CIMR induced progressive increase of daily
furosemide during the follow-up (Table 2). Finally, when pa-
tients with preoperative LVEDD 70 mm or greater were ana-
lyzed, low follow-up freedom from CHF and hospitalization
was found (both 21.2% 17.4%) (Figure 3, A and B). More-
over, compared with patients with preoperative LVEDD lessTABLE 2. Recovery of New York Heart Association class and need for daily diuretic dose in patients with and without chronic ischemic mitral
regurgitation recurrence
Preoperative NYHA Discharge NYHA 6-mo NYHA Follow-up NYHA P* Py
Recurrent CIMR (14 patients) 3.7  0.5 1.8  0.4 2.1  0.7 2.6  0.7 .0001 .0001








furosemide (mg) P* Py
Recurrent CIMR (14 patients) 94.6  49.2 41.1  15.8 60.7  27.2 82.1  28.5 .0001 .0001
No CIMR (44 patients) 73.8  25.8 29.5  10.8 20.4  6.1 15.6  8.5 .003
CIMR, Chronic ischemic mitral regurgitation. *Statistical probability within group. yStatistical probability between groups.ardiovascular Surgery c Volume 138, Number 2 345
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DFIGURE 3. Actuarial freedom from CHF (A), hospitalization (B), and recurrent CIMR (C) between patients with preoperative LVEDD  70 mm and
patients with preoperative LVEDD<70 mm. LVEDD, Left ventricular end-diastolic diameter.than 70 mm, a significantly lower freedom from CHF (P ¼
.001; Figure 3, A) and hospitalization (P ¼ .006; Figure 3,
B), together with a higher recurrence of CIMR (P ¼ .002;
Figure 3, C), was shown.
Echocardiographic Results
A different pattern of left ventricular results was found in
patients with recurrent CIMR and patients without CIMR. In
particular, patients with CIMR correlated with absence of
reverse remodeling of LAD, LVEDD, LVESD, and LVMi
(Table 3). Accordingly, LVEF did not improve during fol-
low-up (Table 3). However, after a significant improvement
of mitral CD at discharge, CD increased parallel to the wors-
ening of CIMR, whereas transmitral mean Dp diminished
(Table 3).
On the other hand, patients without CIMR showed signif-
icant reverse remodeling of LVEDD, LVESD, and LVMi
together with improvement of their LVEF and persistently
shortened CD from discharge to the end of follow-up. These
same patients also showed a higher mean Dp (compared
with patients with recurrent CIMR), which remained stable
during follow-up and is potentially responsible for the ab-346 The Journal of Thoracic and Cardiovascular Susence of LAD reverse remodeling (Table 3). However, apart
from preoperative LVMi, no significant differences were
found in baseline clinical and echocardiographic characteris-
tics between patients with recurrent CIMR and patients with-
out CIMR (Table 4).
When right ventricular echocardiographic results were an-
alyzed, despite the fact that TI improved both in patients
with and without recurrent CIMR, neither group showed
any right-sided heart amelioration in terms of PAPs,
RVEF, and TAPSE (Table 5). In particular, patients with re-
current CIMR evidenced a slight progressive worsening of
PAPs and a slight deterioration of RVEF (although not sta-
tistically significant), without improvement of TAPSE dur-
ing the follow-up. On the other hand, although patients
without CIMR did not show any improvement in PAPs,
RVEF, and TAPSE during follow-up, despite the postoper-
ative reduction of TI grade, they did not have deterioration of
PAPs, RVEF, and TAPSE (Table 5).
Stratification According to Tricuspid Surgery
Subgroup analysis in patients who did not undergo tricus-
pid surgery at the time of RMA demonstrated significantrgery c August 2009
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DTABLE 3. Left-sided heart echocardiographic results
Preoperative CIMR Discharge CIMR 6-mo CIMR Follow-up CIMR P* Py
Recurrent CIMR (14 patients) 3.5  0.5 1.3  0.5 1.9  0.3 2.5  0.5 .381 .0001
No CIMR (44 patients) 3.3  0.5 0.7  0.5 0.6  0.5 0.6  0.5 .0001
Preoperative LAD Discharge LAD 6-mo LAD Follow-up LAD P* Py
Recurrent CIMR (14 patients) 46.6  5.4 46.6  5.4 47.1  5.4 43.7  12.1 .101 .296
No CIMR (44 patients) 45.8  3.7 45.3  3.5 44.2  3.4 43.4  3.4 .087
Preoperative LVEDD Discharge LVEDD 6-mo LVEDD Follow-up LVEDD P* Py
Recurrent CIMR (14 patients) 67.0  8.0 67.1  8.1 67.4  7.9 67.6  7.9 .212 .004
No CIMR (44 patients) 63.8  4.8 62.6  4.7 61.3  4.5 60.4  5.1 .0001
Preoperative LVESD Discharge LVESD 6-mo LVESD Follow-up LVESD P* Py
Recurrent CIMR (14 patients) 55.1  13.3 55.1  13.2 55.2  13.4 55.4  13.1 .748 .014
No CIMR (44 patients) 54.6  6.4 49.5  6.4 47.9  6.2 46.9  5.8 .0001
Preoperative LVMi Discharge LVMi 6-mo LVMi Follow-up LVMi P* Py
Recurrent CIMR (14 patients) 145.3  19.2 145.2  19.2 145.9  19.9 146.4  18.7 .123 .005
No CIMR (44 patients) 138.8  20.1 138.3  19.8 136.4  19.8 134.9  19.6 .002
Preoperative LVEF Discharge LVEF 6-mo LVEF Follow-up LVEF P* Py
Recurrent CIMR (14 patients) 38.1  8.7 35.4  8.1 37.3  9.3 36.7  8.7 .703 .0024
No CIMR (44 patients) 40.1  6.9 38.1  6.8 42.9  6.5 46.6  6.7 .0001
Preoperative CD Discharge CD 6-mo CD Follow-up CD P* Py
Recurrent CIMR (14 patients) 1.3  0.1 0.7  0.1 0.8  0.2 0.8  0.2 .001 .0001
No CIMR (44 patients) 1.3  0.1 0.4  0.1 0.4  0.1 0.5  0.1 .0001
Preoperative mean Dp Discharge mean Dp 6-mo mean Dp Follow-up mean Dp P* Py
Recurrent CIMR (14 patients) 0.9  0.8 4.8  0.8 4.2  0.8 3.8  1.0 .001 .0001
No CIMR (44 patients) 0.9  0.7 5.8  1.1 5.7  1.1 5.8  1.1 .0001
CIMR, Chronic ischemic mitral regurgitation; LAD, left atrial diameter; LVEDD, left ventricular diastolic diameter; LVESD, left ventricular systolic diameter; LVMi, left ventricular
mass index; LVEF, left ventricular ejection fraction; CD, coaptation depth; Dp, pressure gradient. *Statistical probability within group. yStatistical probability between groups.differences in right-sided heart echocardiographic parame-
ters during follow-up. In particular, patients developing re-
currence of CIMR demonstrated a progressive worsening
of TI grade (after an initial early amelioration), with de-
pressed RVEF and TAPSE and high PAPs, whereas patients
without CIMR showed a progressive improvement of TI
grade, PAPs, RVEF, and TAPSE (Table 6). Obviously, pa-
tients with recurrent CIMR demonstrated progressive wors-
ening of NYHA with a greater need for daily diuretics,
whereas patients without CIMR progressively improved
theirNYHAand decreased their daily diuretic dose (Table 6).
On the other hand, patients undergoing tricuspid annulo-
plasty did not demonstrate any improvement of PAPs,
RVEF, and TAPSE during follow-up, regardless of the re-
currence of CIMR. However, in those without CIMR, the
absence of recurrent CIMR together with the effects of the
tricuspid annuloplasty improved TI grade during follow-up
(Table 7), with a significant amelioration of NYHA and a sig-
nificant reduction of the daily diuretic dose, compared with
patients with recurrent CIMR (Table 7).The Journal of Thoracic andDISCUSSION
CIMR is considered to be a common cause of post-
myocardial infarction congestive heart failure and has been
considered one of the few targets for therapeutic opportuni-
ties in patients with heart failure.5 According to the complex
and different pathogenetic mechanisms underlying such dis-
ease, several different surgical techniques have been devel-
oped for CIMR, from RMA to mitral valve replacement,
chordal cutting, papillary imbrication, sling, and reposition-
ing to percutaneous annuloplasty and so on, the majority of
which are still considered experimental.2,5,7
Because of the safety and reproducibility of RMA, our op-
erative mortality (6%) is in line with other studies and well
below the logistic European System for Cardiac Operative
Risk Evaluation for this group.7 Moreover, our favorable
overall midterm outcome with a 2-year actuarial survival of
96% is better than that reported by Grossi and colleagues15
but comparable to that reported by others.16,17 On the other
hand, it is well known that patients with CIMR have a worse
natural history than patients with ischemic heart diseaseCardiovascular Surgery c Volume 138, Number 2 347
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Dwithout CIMR. A study of 11,748 patients who underwent
cardiac catheterization revealed that severe CIMR was asso-
ciated with a 1-year mortality of 40%, moderate CIMR of
17%, and mild CIMR of 10%.18 The SAVE study demon-
strated that mild chronic CIMR increases the risk of cardio-
vascular mortality (29% vs 12%) and heart failure (24% vs
16%) than patients without CIMR at amean of 3.5 years after
myocardial infarction. Adjustment for differences in baseline
characteristics revealed thatmild-to-moderateCIMRstrongly
predicted midterm mortality.19 Therefore, it is not surprising
that patients with recurrent CIMR showed lower survival,
freedom from CHF, hospitalization, and reintervention, to-
gether with a progressive worsening of their NYHA and
need for diuretics, when compared with patients without re-
currences. Our findings correlated with those of De Bonis
and colleagues,20 showing a significantly worse NYHA
when CIMR recurs, and of Gelsomino and colleagues,21
who also found higher NYHA class and reoperation rate in
patients with failed RMA.
TABLE 4. Preoperative clinical and echocardiographic characteristics
between patients who survived more than 6 months with recurrent







Age, y 68.3  3.1 70.2  2.1 .661
Sex (male) 8 (57.1%) 28 (63.6%) .447
Diabetes 8 (57.1%) 20 (45.5%) .324
Hypertension 4 (28.6%) 11 (25.0%) .521
Emergency 2 (14.3%) — .055
Left main stem disease 11 (78.6%) 30 (68.2%) .351
COPD 9 (64.3%) 26 (59.1%) .492
Canadian class score 3.0  0.4 3.1  0.7 .717
NYHA 3.7  0.5 3.3  0.6 .083
No. CABG 1.8  1.0 2.1  0.8 .625
ACC time (min) 72.5  4.9 73.2  4.0 .568
CPB time (min) 137.5  17.2 134.9  10.9 .508
CIMR grade 3.5  0.5 3.3  0.5 .293
LAD 46.6  5.4 45.8  3.7 .543
LVEDD 67.0  8.0 63.8  4.8 .081
LVESD 55.1  13.3 54.6  6.4 .087
LVMi 145.3  19.2 138.8  20.1 .039
LVEF 38.1  8.7 40.1  6.9 .386
CD 1.3  0.1 1.3  0.1 .919
Mean transmitral Dp 0.9  0.8 0.9  0.7 .813
TI grade 2.1  0.6 1.9  0.5 .590
PAPs 38.5  9.2 37.4  6.5 .635
TAPSE 16.1  2.6 15.9  2.3 .774
RVEF 39.3  8.8 40.5  9.6 .672
COPD, Chronic obstructive pulmonary disease; NYHA, New York Heart Association;
ACC, aortic crossclamp; CPB, cardiopulmonary bypass; CIMR, chronic obstructive
pulmonary disease; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic
volume; LVESD, left ventricular end-systolic volume; LVMi, indexed left ventricular
mass; LVEF, left ventricular ejection fraction; CD, coaptation depth; TI, tricuspid in-
sufficiency; PAPs, systolic pulmonary arterial pressure; TAPSE, tricuspid annular
plane systolic excursion; RVEF, right ventricular ejection fraction.348 The Journal of Thoracic and Cardiovascular SuRMA has been successfully used by Bolling and col-
leagues22 for more than a decade. Despite the enthusiasm
for the low perioperative mortality rates and the positive ef-
fects on survival, CHF, and functional NYHA class, several
studies have clearly addressed that RMA is affected by a vari-
able recurrence rate.2,5,7,15-21 A recent article examined 585
patients undergoing RMA over a 17-year period: In 28%
of patients, moderate or more mitral regurgitation developed
6 months postoperatively, an incidence that is similar to that
described by other investigators.23 Although recurrence
tends to occur early postoperativelywith relatively low recur-
rence rates thereafter,24 progressive ventricular dilation and
ongoing cardiomyopathy seem to be responsible for recur-
rence rate during follow-up.7,21,24-26 Preoperative highly re-
modeled left ventricles are considered to have a poor success
rate at follow-up: Braun and colleagues7 showed preopera-
tive LVEDD greater than 65 mm to correlate with higher re-
currence of CIMR with worse survival and NYHA class.
Gelsomino and colleagues21 found large ventricular volumes
and high sphericity index to be predictive of an absence of re-
verse remodeling and a higher recurrence rate. Roshanali and
colleagues25 showed preoperative interpapillary muscle dis-
tance to be related to recurrent CIMR during follow-up. Cal-
afiore and colleagues26 demonstrated high preoperative CD
more than 10 mm to correlate with recurrence. We found
24% CIMR recurrence, with a slightly lower freedom from
CIMR during follow-up compared with previous stud-
ies,2,7,21,23 possibly because of the slightly worse profile of
preoperative echocardiographic parameters of our popula-
tion (LVEDD 64–67 mm and CD>13 mm in almost all pa-
tients). According to previous series,2,7,21,24-26 our patients
demonstrating recurrent CIMR showed slightly higher pre-
operative LVEDD and LVESD, confirming that a higher de-
gree of preoperative ventricular remodeling may correlate
with RMA failure. Furthermore, according to Braun and col-
leagues,7 successful RMAcuredCIMR, also correlatingwith
reverse remodeling of LVEDD, LVESD, and LVMi in our
population. However, whether the recurrence ofCIMRantic-
ipates the absence of reverse remodeling of LVEDD,
LVESD, and LVMi, or the absence of reverse remodeling
of LVEDD, LVESD, and LVMi determines the recurrence
of CIMR should be the topic of future studies. Moreover,
we found a different pattern of echocardiographic CD and
mean transmitral Dp in patients with or without recurrence.
In particular, patients without CIMR showed lower CD at
discharge, parallel to high mean Dp. Both indexes remained
stable during follow-up. On the other hand, patients in whom
RMA failed demonstrated deeper CD at discharge with a low
mean transmitralDp, which worsened further during follow-
up. These data confirm CD as a reliable index of recurrent
CIMR.25,26 Moreover, subgroup analysis in patients with
preoperative severe dilation of the left ventricle (LVEDD
>70 mm) confirmed that these patients, as previously de-
scribed,7 had a worse prognosis in terms of CHF.rgery c August 2009
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DTABLE 5. Right-sided heart echocardiographic results
Preoperative TI Discharge TI 6-mo TI Follow-up TI P* Py
Recurrent CIMR (14 patients) 2.1  0.6 1.1  0.3 1.1  0.3 1.2  0.4 .001 .540
No CIMR (44 patients) 1.9  0.5 1.1  0.2 1.1  0.2 1.1  0.4 .001
Preoperative PAPs Discharge PAPs 6-mo PAPs Follow-up PAPs P* Py
Recurrent CIMR (14 patients) 38.5  9.2 36.3  7.4 39.5  6.9 40.8  6.6 .788 .353
No CIMR (44 patients) 37.4  6.5 35.2  5.9 36.6  6.9 38.4  7.3 .261
Preoperative TAPSE Discharge TAPSE 6-mo TAPSE Follow-up TAPSE P* Py
Recurrent CIMR (14 patients) 16.1  2.6 15.6  2.6 15.8  2.5 15.9  2.6 .105 .793
No CIMR (44 patients) 15.9  2.3 15.1  2.2 15.7  1.9 16.1  2.1 .083
Preoperative RVEF Discharge RVEF 6-mo RVEF Follow-up RVEF P* Py
Recurrent CIMR (14 patients) 39.3  8.8 37.3  8.6 38.8  8.2 37.3  8.6 .207
No CIMR (44 patients) 40.5  9.6 39.5  9.9 40.2  9.8 40.5  9.8 .149 .637
TI, Tricuspid insufficiency; PAPs, systolic pulmonary arterial pressure; TAPSE, tricuspid annular plane systolic excursion. *Statistical probability within group. yStatistical prob-
ability between groups.If general agreement exists on the beneficial effects of
RMA on left ventricular remodeling, little is known of the
fate of the right chambers. A recent study showed the poten-
tial of RMA to induce iatrogenic mitral stenosis.8 Functional
TI is often associated with mitral valve disease and thought
to be caused by dilatation of the tricuspid annulus and teth-
ering of the tricuspid leaflets resulting from right ventricular
dilatation.27 Functional tricuspid regurgitation is now en-The Journal of Thoracic and Ccountered regularly in patients with severe left ventricular
dysfunction who undergo cardiac operations.7,8,28-32
Tricuspid annuloplasty represents the common surgical
strategy, although the rate of recurrent regurgitation remains
high.28,29 Moreover, most of the data available on the
outcome of functional tricuspid regurgitation after mitral
surgery come from series of patients affected by degenera-
tive28 or rheumatic mitral disease,30 whereas only fewTABLE 6. Right-sided heart echocardiographic and functional results in patients without tricuspid annuloplasty
Preoperative TI Discharge TI 6-mo TI Follow-up TI P* Py
Recurrent CIMR (8 patients) 1.8  0.4 1.1  0.3 1.3  0.5 1.8  0.7 .013 .0001
No CIMR (34 patients) 1.8  0.4 1.0  0.2 1.0  .02 1.0  0.1 .0001
Preoperative PAPs Discharge PAPs 6-mo PAPs Follow-up PAPs P* Py
Recurrent CIMR (8 patients) 35.9  8.2 34.2  5.6 35.8  4.7 35.0  7.9 .336 .0001
No CIMR (34 patients) 37.9  5.1 30.8  3.8 28.  4.2 27.6  3.7 .0001
Preoperative TAPSE Discharge TAPSE 6-mo TAPSE Follow-up TAPSE P* Py
Recurrent CIMR (8 patients) 17.0  2.8 16.8  2.9 16.8  2.8 16.9  2.9 .555 .0001
No CIMR (34 patients) 15.1  2.5 15.2  2.3 16.8  2.1 18.3  2.3 .0001
Preoperative RVEF Discharge RVEF 6-mo RVEF Follow-up RVEF P* Py
Recurrent CIMR (8 patients) 44.5  8.8 39.4  8.7 40.7  8.5 39.3  8.6 .073 .0001
No CIMR (34 patients) 44.8  7.9 45.0  8.5 48.3  8.8 48.8  8.4 .009
Preoperative NYHA Discharge NYHA 6-mo NYHA Follow-up NYHA P* Py
Recurrent CIMR (8 patients) 3.5  0.5 1.8  0.4 2.0  0.7 2.5  0.7 .003 .0001








furosemide (mg) P* Py
Recurrent CIMR (8 patients) 77.8  23.2 36.1  13.2 50.0  21.6 75.0  30.6 .008 .0001
No CIMR (34 patients) 75.7  25.3 29.5  11.2 21.2  5.8 17.0  8.2 .0001
TI, Tricuspid insufficiency; PAPs, systolic pulmonary arterial pressure; TAPSE, tricuspid annular plane systolic excursion. *Statistical probability within group. yStatistical prob-
ability between groups.ardiovascular Surgery c Volume 138, Number 2 349
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DTABLE 7. Right-sided heart echocardiographic and functional results in patients with tricuspid annuloplasty
Preoperative TI Discharge TI 6-mo TI Follow-up TI P* Py
Recurrent CIMR (6 patients) 2.6  0.5 1.6  0.5 1.8  0.8 2.4  0.5 .411 .010
No CIMR (10patients) 2.5  0.5 1.3  0.5 1.3  0.5 1.3  0.8 .004
Preoperative PAPs Discharge PAPs 6-mo PAPs Follow-up PAPs P* Py
Recurrent CIMR (6 patients) 49.0  8.2 41.0  10.2 45.0  11.7 45.2  11.5 .854 .126
No CIMR (10 patients) 44.5  5.7 42.1  10.1 43.2  7.5 42.7  8.4 .181
Preoperative TAPSE Discharge TAPSE 6-mo TAPSE Follow-up TAPSE P* Py
Recurrent CIMR (6 patients) 14.6  1.1 14.4  1.2 14.4  0.8 14.5  0.7 .638 .300
No CIMR (10 patients) 15.5  1.8 14.7  1.9 15.4  1.5 15.5  1.4 .978
Preoperative RVEF Discharge RVEF 6-mo RVEF Follow-up RVEF P* Py
Recurrent CIMR (6 patients) 31.8  2.3 30.3  2.7 32.4  2.6 33.1  3.2 .218 .929
No CIMR (10 patients) 32.0  1.9 31.0  1.8 32.0  1.9 32.2  2.2 .307
Preoperative NYHA Discharge NYHA 6-mo NYHA Follow-up NYHA P* Py
Recurrent CIMR (6 patients) 3.9  0.2 2.0  0.3 2.4  0.5 2.8  0.8 .033 .0001








furosemide (mg) P* Py
Recurrent CIMR (6 patients) 85.0  70.0 50.0  17.6 80.0  27.4 95.0  20.9 .010 .0001
No CIMR (10 patients) 88.2  27.5 29.5  10.1 18.2  6.5 11.4  8.8 .001
TI, Tricuspid insufficiency; PAPs, systolic pulmonary arterial pressure; TAPSE, tricuspid annular plane systolic excursion; CIMR, chronic obstructive pulmonary disease.
*Statistical probability within group. yStatistical probability between groups.reports deal with regurgitation of the tricuspid valve in the
context of dilated cardiomyopathy.8,29 Our population sub-
stantially showed little impact of RMA on right-sided heart
evolution. Obviously, when CIMR recurred, the persistence
of the left-sided disease did not ameliorate TI, PAPs, RVEF,
and TAPSE, regardless of whether patients underwent tri-
cuspid annuloplasty at the time of RMA. It was recently
demonstrated that the progression or recurrence of signifi-
cant TI occurred among patients who did not show signs
of reverse left ventricular remodeling after magnetic reso-
nance angiography for dilated cardiomyopathy.27 Di Mauro
and colleagues31 demonstrated right ventricular dysfunction
in patients undergoing RMA, which correlated with worsen-
ing NYHA and reduced survival. Accordingly, our patients
with failed RMA not only demonstrated the absence of left-
heart reverse remodeling but also failed to improve their TI,
PAPs, RVEF, and TAPSE. Furthermore, they had to in-
crease their daily dose of diuretics and worsened their
NYHA whenever CIMR recurred in patients without previ-
ous tricuspid surgery.
On the other hand, patients without CIMR showed a com-
pletely different evolution of the right chambers, based on
the need for tricuspid surgery at the time of RMA. Patients
without CIMR who did not undergo tricuspid annuloplasty
at the time of RMA demonstrated progressive amelioration
of TI grade, along with PAPs, RVEF, and TAPSE, whereas
patients undergoing tricuspid surgery at the time of RMA350 The Journal of Thoracic and Cardiovascular Sudid not show improved PAPs, RVEF, and TAPSE despite
good functional results of the RMA itself. Dreyfus and col-
leagues32 clearly demonstrated that tricuspid annular dilata-
tion is an ongoing process, advocating that any patient with
substantial annular dilatation should undergo repair regard-
less of the TI grade. Matsuyama and associates33 reported
that 16% of the patients who underwent mitral valve surgery
without concomitant tricuspid valve surgery developed 3þto
4þTI at an 8-year follow-up.
CONCLUSIONS
Our results show that patients undergoing tricuspid sur-
gery have a worse echocardiographic profile compared
with those not undergoing tricuspid annuloplasty, being pa-
tients with an already compromised right ventricle at the
time of surgery (low TAPSE and RVEF, high PAPs). These
patients therefore have a reduced possibility of reverse re-
modeling of the right side of the heart. It is well known
that ventricular dilation or severe tethering before surgery
anticipates TI recurrence despite annuloplasty.34 Moreover,
it can be speculated that in this subset of patients, the higher
mean transmitral Dp (demonstrated in patients without
CIMR during follow-up) may act as a ‘‘iatrogenic’’ mild mi-
tral stenosis, preserving the left ventricle from progressive
dilation but further overloading an already diseased right
ventricle.8 The absence of left ventricular remodeling in pa-
tients with a severely dilated left ventricle identifies a morergery c August 2009
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Dadvanced ‘‘left-sided’’ stage of the disease (with poor out-
come after isolated RMA), where the left ventricle itself
needs to be addressed.7 Accordingly, it can be hypothesized
that the need for tricuspid annuloplasty at the time of RMA
identifies a more advanced ‘‘right-sided’’ stage of cardiomy-
opathy, where tricuspid annuloplasty itself is not sufficient
to improve the right side of the heart, further overloaded
by an increased pulmonary pressure induced by RMA itself.
However, the absence of CIMR together with the effect of
tricuspid surgery in this highly diseased category of patients
avoids volume overload on an already compromised right
ventricle, leading at least to a better NYHA class (and lower
diuretic need) compared with patients with CIMR recur-
rence. Therefore, only patients undergoing mitral surgery
without functional tricuspid disease may benefit from
RMA alone. However, further studies addressing right heart
evolution after RMA in patients with ischemic dilated car-
diomyopathy are needed to clarify such a topic.
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